A Cost Analysis of Pathology Evaluation of Carotid Plaque after Endarterectomy

Ann Vasc Surg. 2020 Aug:67:208-212. doi: 10.1016/j.avsg.2020.04.065. Epub 2020 May 18.

Abstract

Background: Overtreatment and overuse of resources are leading causes of rising health care costs. Identification and elimination process of low value services is important in reducing such costs. At many institutions it is routine to send excised plaque after carotid endarterectomy (CEA) for pathology evaluation. With more than 140,000 CEAs performed annually in the United States, this represents an opportunity for potential cost savings. We set out to examine the cost and clinical use of pathology evaluation of plaque after CEA.

Methods: We performed a retrospective review of patients undergoing CEA at a single institution from 2016 to 2019. Patients were excluded if they had a prolonged postoperative length of stay or if they had a preoperative stroke. Demographics, perioperative outcomes, and billing costs were recorded.

Results: We identified 82 total CEAs, of which 42 were excluded according to the aforementioned exclusion criteria. We reviewed 40 CEAs. Mean age of this cohort was 67.2 (±8.3) years. Most (72.5%) were asymptomatic at the time of admission, whereas 27.5% presented with a transient ischemic attack. Mean postoperative length of stay was 1.8 days. The primary insurers were 39.5% private, 39.5% Medicare, and 21.1% Medicaid. Mean total charges for the hospitalization were $83,367 (±$42,874). Of this total, professional fees were $3,512 (±$980) and facility fees were $80,395 (±$42,886). Mean pathology charges were $285 (±$88). The pathology professional fee was $61 (±$27), which represented 1.82% (±0.88) of the professional costs. Reimbursement for the facility pathology charge was $229 (±$57) and for the professional pathology charge was $25 (±$14). All plaque samples were submitted for gross examination and hematoxylin and eosin staining. The correlation rate for the clinical and pathologic diagnosis was 100%. The pathology reports simply read "atherosclerotic plaque" and "calcific plaque" in 32.5% and 45% of samples. For the remaining plaques, 12.5% and 10% of reports also noted fibrosis and degenerative changes, respectively. There were no clinical implications or decisions made based on the pathology reports. Cost of pathology evaluation was on average $285, with an average reimbursement of $235. With 140,000 CEAs done annually, this represents a potential $32.9-$39.9 million saved to the health care system.

Conclusions: Pathology evaluation of carotid plaque incurs significant costs to the health care system with no clear value for the postoperative care of the patient. Hospital policy regarding mandatory pathologic examination and surgeon preferences regarding plaque analysis should be more closely examined.

MeSH terms

  • Aged
  • Biopsy / economics
  • Carotid Arteries / pathology
  • Carotid Arteries / surgery*
  • Carotid Artery Diseases / economics*
  • Carotid Artery Diseases / pathology
  • Carotid Artery Diseases / surgery*
  • Cost Savings
  • Cost-Benefit Analysis
  • Endarterectomy, Carotid / economics*
  • Female
  • Hospital Costs*
  • Humans
  • Insurance, Health, Reimbursement / economics
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care / economics*
  • Plaque, Atherosclerotic*
  • Postoperative Care / economics*
  • Predictive Value of Tests
  • Retrospective Studies
  • Treatment Outcome
  • Unnecessary Procedures / economics